A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

• ClinicalTrials.gov Identifier: NCT02367781
• Recruitment Status: Completed
• First Posted: February 20, 2015
• Results First Posted: April 3, 2019
• Last Update Posted: August 9, 2021
• Sponsor: Hoffmann-La Roche
• Information provided by (Responsible Party): Hoffmann-La Roche

• Study Type: Interventional
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Carcinoma, Non-Squamous Non-Small Cell Lung
• Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Drug: Carboplatin; Drug: Nab-Paclitaxel; Drug: Pemetrexed
• Enrollment: 723

Participant Flow

Recruitment Details

Pre-assignment Details

Participants in this study included: histologically or cytologically confirmed, Stage IV non-squamous NSCLC; and no prior treatment for Stage IV non-squamous NSCLC. At the time of study completion a few participants that were still on maintenance treatment with atezolizumab were moved to another study, Post-Trial Access Program, or commercial use. Therefore, the reason for discontinuation was entered "Study terminated by Sponsor" for these participants.

Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Period Title: Overall Study
Started	483	240
Completed	0	0
Not Completed	483	240
Reason Not Completed
Withdrawal by Subject	20	13
Protocol Violation	0	1
Physician Decision	7	0
Randomized in Error	5	4
Non-Compliance	1	0
Lost to Follow-up	1	2
Death	330	176
Patient Moving to Roll-Over Study	17	5
Prolonged Hospitalization	1	0
Death Prior First Dose	1	0
Administrative-Change Facility	1	0
Request From Sponsor to Withdraw Patient in Survival Follow-Up	78	29
Patient Moved to Commercial Atezolizumab Use	14	9
Study Terminated by Sponsor	3	1
Patient Admitted to Hospital & Couldn't be Dosed for Randomization	1	0
Sponsor Decision	2	0
3 Year Treatment Completed, Immunotherapy Paused, Continuing Follow-Up Planned	1	0

Baseline Characteristics

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)	Total
Arm/Group Description		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.	Total of all reporting groups
Overall Number of Baseline Participants		483	240	723
Baseline Analysis Population Description		[Not Specified]
Age, Continuous; Mean (Standard Deviation); Unit of measure: Years
	Number Analyzed	483 participants	240 participants	723 participants
		63.8 (9.5)	64.4 (8.9)	64.0 (9.3)
Sex: Female, Male; Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	483 participants	240 participants	723 participants
	Female	206 42.7%	102 42.5%	308 42.6%
	Male	277 57.3%	138 57.5%	415 57.4%
Ethnicity (NIH/OMB); Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	483 participants	240 participants	723 participants
	Hispanic or Latino	25 5.2%	12 5.0%	37 5.1%
	Not Hispanic or Latino	426 88.2%	213 88.8%	639 88.4%
	Unknown or Not Reported	32 6.6%	15 6.3%	47 6.5%
Race (NIH/OMB); Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	483 participants	240 participants	723 participants
	American Indian or Alaska Native	0 0.0%	0 0.0%	0 0.0%
	Asian	14 2.9%	3 1.3%	17 2.4%
	Native Hawaiian or Other Pacific Islander	0 0.0%	0 0.0%	0 0.0%
	Black or African American	18 3.7%	8 3.3%	26 3.6%
	White	428 88.6%	222 92.5%	650 89.9%
	More than one race	2 0.4%	0 0.0%	2 0.3%
	Unknown or Not Reported	21 4.3%	7 2.9%	28 3.9%

Outcome Measures

1. Primary Outcome

Title	Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population
Description	PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first in the ITT-WT population.
Time Frame	Up to approximately 35 months after first patient enrolled

Outcome Measure Data

Analysis Population Description

The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation.

Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed	456	229
Median (95% Confidence Interval); Unit of Measure: Months
	7.0; (6.3 to 7.3)	5.5; (4.4 to 5.9)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Statistical Test of Hypothesis	P-Value	<.0001
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.639
	Confidence Interval	(2-Sided) 95%; 0.536 to 0.763
	Estimation Comments	[Not Specified]

2. Primary Outcome

Title	Overall Survival (OS) in the ITT-WT Population
Description	OS is defined as the time between the date of randomization and date of death from any cause in the ITT-WT population.
Time Frame	Up to approximately 35 months after first patient enrolled

Outcome Measure Data

Analysis Population Description

The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation.

Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed	456	229
Median (95% Confidence Interval); Unit of Measure: Months
	18.6; (15.8 to 21.2)	13.9; (12.0 to 18.7)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Statistical Test of Hypothesis	P-Value	0.0298
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.788
	Confidence Interval	(2-Sided) 95%; 0.636 to 0.977
	Estimation Comments	[Not Specified]

3. Secondary Outcome

Title	PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
Description	PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time Frame	Up to approximately 35 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		483	240
Median (95% Confidence Interval); Unit of Measure: Months
ITT Population	Number Analyzed	483 participants	240 participants
		7.0; (6.3 to 7.3)	5.6; (4.5 to 5.9)
TC1/2/3 or IC1/2/3 ITT Population	Number Analyzed	230 participants	111 participants
		7.5; (7.0 to 9.1)	5.7; (4.5 to 6.6)
TC1/2/3 or IC1/2/3-WT ITT Population	Number Analyzed	216 participants	107 participants
		7.5; (7.0 to 9.0)	5.9; (4.5 to 6.6)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	ITT Population
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.647
	Confidence Interval	(2-Sided) 95%; 0.545 to 0.768
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3-WT ITT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.561
	Confidence Interval	(2-Sided) 95%; 0.432 to 0.728
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3 ITT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.549
	Confidence Interval	(2-Sided) 95%; 0.425 to 0.708
	Estimation Comments	[Not Specified]

4. Secondary Outcome

Title	OS as Determined by the Investigator Using Recist v1.1 in the ITT Population
Description	OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.
Time Frame	Up to approximately 41 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment.

Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed	483	240
Median (95% Confidence Interval); Unit of Measure: Months
	17.0; (14.9 to 19.7)	13.5; (11.9 to 17.7)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Statistical Test of Hypothesis	P-Value	0.0732
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.837
	Confidence Interval	(2-Sided) 95%; 0.689 to 1.017
	Estimation Comments	[Not Specified]

5. Secondary Outcome

Title	OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population
Description	OS is defined as the time between the date of randomization and date of death from any cause in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time Frame	Up to approximately 35 months after first patient enrolled

Outcome Measure Data

Analysis Population Description

PD-L1 Expression Population and PD-L1 Expression WT Population

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		230	111
Median (95% Confidence Interval); Unit of Measure: Months
TC1/2/3 or IC1/2/3 ITT Population	Number Analyzed	230 participants	111 participants
		21.2; (17.3 to 28.2)	16.9; (12.5 to 22.0)
TC1/2/3 or IC1/2/3 WT ITT Population	Number Analyzed	216 participants	107 participants
		21.2; (18.1 to 28.2)	16.9; (12.5 to 22.0)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3 ITT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	0.0830
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.752
	Confidence Interval	(2-Sided) 95%; 0.545 to 1.039
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3 WT ITT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	0.0813
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.746
	Confidence Interval	(2-Sided) 95%; 0.536 to 1.038
	Estimation Comments	[Not Specified]

6. Secondary Outcome

Title	Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population
Description	ORR (confirmation not required) is defined as the proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by the investigator in the ITT-WT population.
Time Frame	Up to approximately 41 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation

Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed	452	227
Measure Type: Number; Unit of Measure: Percentage of participants
	60.2	41.0

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Statistical Test of Hypothesis	P-Value	<.0001
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Response Rate
	Estimated Value	19.21
	Confidence Interval	(2-Sided) 95%; 11.05 to 27.37
	Estimation Comments	Wald with Continuity Correction

7. Secondary Outcome

Title	Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
Description	ORR (confirmation not required) is defined as proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by investigator in ITT population, PD-L1 Expression population, and PD-L1 Expression WT population. ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. PD-L1 expression WT population is defined as PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time Frame	Up to approximately 35 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		479	237
Measure Type: Number; Unit of Measure: Percentage of participants
ITT Population	Number Analyzed	479 participants	237 participants
		59.1	42.2
TC1/2/3 or IC1/2/3 ITT WT Population	Number Analyzed	215 participants	106 participants
		65.6	46.2
TC1/2/3 or IC1/2/3 ITT Population	Number Analyzed	229 participants	109 participants
		64.6	45.0

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	ITT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	<.0001
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Response Rate
	Estimated Value	16.89
	Confidence Interval	(2-Sided) 95%; 8.90 to 24.88
	Estimation Comments	Wald with Continuity Correction

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3 ITT WT Population
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.22
	Confidence Interval	(2-Sided) 95%; 1.38 to 3.56
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3 ITT Population
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Statistical Test of Hypothesis	P-Value	0.0007
	Comments	[Not Specified]
	Method	Cochran-Mantel-Haenszel
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.21
	Confidence Interval	(2-Sided) 95%; 1.39 to 3.51
	Estimation Comments	[Not Specified]

8. Secondary Outcome

Title	Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population
Description	DOR,defined for participants with objective response (OR) as time from 1st documented OR to documented disease progression as determined by investigator using RECIST v1.1,or death from any cause,whichever occurs 1st.ITT defined as all randomized participants,regardless of receipt of assigned treatment.ITT-WT defined as ITT population excluding participants with activating EGFR mutation or ALK translocation.PD-L1 expression population is defined as one of following:PD-L1 IHC TC1/2/3 or IC1/2/3 population,defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue;PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue;PD-L1 IHC TC3 or IC3 population,defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue.PD-L1 expression WT is defined as PD-L1 expression population excluding participants with activating EGFR mutation or ALK translocation.
Time Frame	Up to approximately 35 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-l1 Expression WT Population

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		283	100
Median (95% Confidence Interval); Unit of Measure: Months
ITT Population	Number Analyzed	283 participants	100 participants
		6.2; (5.6 to 7.9)	5.4; (4.1 to 5.8)
ITT-WT Population	Number Analyzed	267 participants	93 participants
		6.7; (5.6 to 8.0)	5.4; (3.9 to 5.8)
TC1/2/3 or IC1/2/3 ITT Population	Number Analyzed	148 participants	49 participants
		7.2; (5.7 to 9.0)	5.0; (3.2 to 6.1)
TC1/2/3 or IC1/2/3 ITT WT Population	Number Analyzed	141 participants	49 participants
		7.2; (5.7 to 9.0)	5.0; (3.2 to 6.1)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	ITT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	0.0002
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.614
	Confidence Interval	(2-Sided) 95%; 0.473 to 0.797
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	ITT-WT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	0.0002
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.600
	Confidence Interval	(2-Sided) 95%; 0.458 to 0.785
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3 ITT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	0.0011
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.548
	Confidence Interval	(2-Sided) 95%; 0.379 to 0.791
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	TC1/2/3 or IC1/2/3 ITT WT Population
	Type of Statistical Test	Superiority
	Comments	Unstratified Analysis
Statistical Test of Hypothesis	P-Value	0.0014
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.551
	Confidence Interval	(2-Sided) 95%; 0.381 to 0.798
	Estimation Comments	[Not Specified]

9. Secondary Outcome

Title	Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population
Description	The OS rate at the 1- and 2-year landmark time points after randomization.
Time Frame	Up to 41 months after first patient enrolled, years 1 and 2 reported

Outcome Measure Data

Analysis Population Description

The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment.

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		483	240
Measure Type: Number; Number (95% Confidence Interval); Unit of Measure: Percentage of participants
Event Free Rate (%) at Year 1 ITT WT	Number Analyzed	456 participants	229 participants
		62.02; (57.53 to 66.51)	54.56; (48.04 to 61.08)
Event Free Rate (%) at Year 2 ITT WT	Number Analyzed	456 participants	229 participants
		40.43; (35.64 to 45.22)	32.36; (25.80 to 38.92)
Event Free Rate (%) at Year 1 ITT	Number Analyzed	483 participants	240 participants
		61.65; (57.29 to 66.02)	54.47; (48.09 to 60.84)
Event Free Rate (%) at Year 2 ITT	Number Analyzed	483 participants	240 participants
		39.73; (35.10 to 44.37)	32.21; (25.79 to 38.63)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) at Year 1 ITT WT Population
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0647
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	7.46
	Confidence Interval	(2-Sided) 95%; -0.45 to 15.37
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) at Year 2 ITT WT Population
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0516
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	8.07
	Confidence Interval	(2-Sided) 95%; -0.06 to 16.19
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) at Year 1 ITT Population
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0683
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	7.19
	Confidence Interval	(2-Sided) 95%; -0.54 to 14.91
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) at Year 2 ITT Population
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0625
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	7.53
	Confidence Interval	(2-Sided) 95%; -0.39 to 15.44
	Estimation Comments	[Not Specified]

10. Secondary Outcome

Title	Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population
Description	The OS rate at the 1- and 2-year landmark time points after randomization in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Time Frame	Up to 35 months after first patient enrolled, years 1 and 2 reported

Outcome Measure Data

Analysis Population Description

PD-L1 Expression Population and PD-L1 Expression WT Population

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		230	111
Measure Type: Number; Number (95% Confidence Interval); Unit of Measure: Percentage of participants
Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT	Number Analyzed	230 participants	111 participants
		68.56; (62.46 to 74.66)	61.86; (52.55 to 71.17)
Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT	Number Analyzed	230 participants	111 participants
		44.63; (35.99 to 53.27)	35.98; (23.25 to 48.72)
Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT WT	Number Analyzed	216 participants	107 participants
		68.84; (62.56 to 75.13)	62.51; (53.07 to 71.94)
Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT WT	Number Analyzed	216 participants	107 participants
		44.02; (34.86 to 53.18)	35.33; (22.06 to 48.60)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.2385
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	6.69
	Confidence Interval	(2-Sided) 95%; -4.44 to 17.83
	Estimation Comments	[Not Specified]

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.2710
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	8.64
	Confidence Interval	(2-Sided) 95%; -6.75 to 24.03
	Estimation Comments	[Not Specified]

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) Year 1 TC1/2/3 or IC1/2/3 ITT WT
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.2733
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	6.34
	Confidence Interval	(2-Sided) 95%; -5.00 to 17.67
	Estimation Comments	[Not Specified]

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	Event Free Rate (%) Year 2 TC1/2/3 or IC1/2/3 ITT WT
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.2909
	Comments	[Not Specified]
	Method	Z-test
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Difference in Event Free Rate
	Estimated Value	8.69
	Confidence Interval	(2-Sided) 95%; -7.44 to 24.81
	Estimation Comments	[Not Specified]

11. Secondary Outcome

Title	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population
Description	Defined as time from randomization to confirmed deterioration (10-point change) on the combined European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30) and supplemental lung cancer module (EORTC QLQ-LC13) symptom subscales.
Time Frame	Up to approximately 35 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation.

Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed	451	228
Median (95% Confidence Interval); Unit of Measure: Months
	2.2; (1.8 to 3.1)	1.9; (1.5 to 2.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin)
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	Stratified Analysis
Statistical Test of Hypothesis	P-Value	0.3342
	Comments	[Not Specified]
	Method	Log Rank
	Comments	[Not Specified]
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.893
	Confidence Interval	(2-Sided) 95%; 0.711 to 1.123
	Estimation Comments	[Not Specified]

12. Secondary Outcome

Title	Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale
Description	Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant.
Time Frame	Up to approximately 35 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

Patient-reported outcome (PRO) analysis were conducted on either the ITT-WT population or the PRO-evaluable WT population, defined as participants randomized into the ITT-WT population who completed a given PRO questionnaire at the baseline visit and at least one post-baseline visit.

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		236	129
Mean (Standard Deviation); Unit of Measure: Units on a scale
Chest Pain, Week 1	Number Analyzed	203 participants	114 participants
		0.19 (0.86)	0.14 (0.90)
Chest Pain, Week 2	Number Analyzed	204 participants	108 participants
		-0.02 (0.89)	0.03 (0.91)
Chest Pain, Week 3	Number Analyzed	197 participants	106 participants
		-0.05 (0.95)	0.01 (0.92)
Chest Pain, Week 4	Number Analyzed	190 participants	102 participants
		-0.11 (0.95)	0.01 (1.02)
Chest Pain, Week 5	Number Analyzed	192 participants	97 participants
		-0.12 (0.99)	0.00 (1.03)
Chest Pain, Week 6	Number Analyzed	182 participants	98 participants
		-0.24 (1.07)	0.03 (1.03)
Chest Pain, Week 7	Number Analyzed	176 participants	87 participants
		-0.23 (1.11)	0.03 (1.08)
Chest Pain, Week 8	Number Analyzed	169 participants	80 participants
		-0.21 (0.99)	-0.14 (1.00)
Chest Pain, Week 9	Number Analyzed	172 participants	80 participants
		-0.18 (1.07)	-0.01 (1.07)
Chest Pain, Week 10	Number Analyzed	166 participants	75 participants
		-0.10 (1.07)	-0.07 (1.01)
Chest Pain, Week 11	Number Analyzed	171 participants	78 participants
		-0.11 (1.14)	0.01 (0.96)
Chest Pain, Week 12	Number Analyzed	160 participants	72 participants
		-0.15 (1.09)	-0.10 (1.13)
Chest Pain, Week 13	Number Analyzed	151 participants	61 participants
		-0.26 (1.07)	-0.03 (1.02)
Chest Pain, Week 14	Number Analyzed	144 participants	62 participants
		-0.28 (1.08)	-0.17 (1.18)
Chest Pain, Week 15	Number Analyzed	143 participants	51 participants
		-0.26 (1.14)	-0.19 (1.19)
Chest Pain, Week 16	Number Analyzed	139 participants	52 participants
		-0.33 (1.11)	-0.16 (1.20)
Chest Pain, Week 17	Number Analyzed	145 participants	53 participants
		-0.33 (1.11)	-0.14 (1.13)
Chest Pain, Week 18	Number Analyzed	136 participants	49 participants
		-0.28 (1.08)	-0.07 (1.13)
Chest Pain, Week 19	Number Analyzed	124 participants	45 participants
		-0.28 (1.04)	-0.16 (1.00)
Chest Pain, Week 20	Number Analyzed	123 participants	43 participants
		-0.26 (1.03)	-0.22 (1.02)
Chest Pain, Week 21	Number Analyzed	126 participants	41 participants
		-0.25 (1.04)	-0.32 (1.08)
Chest Pain, Week 22	Number Analyzed	116 participants	37 participants
		-0.28 (1.01)	-0.11 (1.03)
Chest Pain, Week 23	Number Analyzed	122 participants	35 participants
		-0.24 (1.03)	-0.19 (1.04)
Chest Pain, Week 24	Number Analyzed	110 participants	34 participants
		-0.21 (1.01)	-0.43 (1.03)
Chest Pain, Week 25	Number Analyzed	104 participants	31 participants
		-0.20 (0.98)	-0.24 (1.07)
Chest Pain, Week 26	Number Analyzed	109 participants	31 participants
		-0.17 (1.01)	-0.13 (0.91)
Chest Pain, Week 27	Number Analyzed	102 participants	27 participants
		-0.22 (1.01)	-0.15 (1.17)
Chest Pain, Week 28	Number Analyzed	96 participants	28 participants
		-0.20 (0.98)	-0.07 (0.91)
Chest Pain, Week 29	Number Analyzed	104 participants	27 participants
		-0.27 (1.09)	-0.04 (0.92)
Chest Pain, Week 30	Number Analyzed	100 participants	23 participants
		-0.15 (1.06)	-0.28 (1.12)
Chest Pain, Week 31	Number Analyzed	93 participants	25 participants
		-0.16 (0.95)	-0.12 (1.05)
Chest Pain, Week 32	Number Analyzed	88 participants	25 participants
		-0.19 (0.89)	-0.30 (1.10)
Chest Pain, Week 33	Number Analyzed	88 participants	25 participants
		-0.18 (1.00)	-0.18 (1.11)
Chest Pain, Week 34	Number Analyzed	85 participants	24 participants
		-0.18 (1.07)	-0.17 (1.18)
Chest Pain, Week 35	Number Analyzed	87 participants	20 participants
		-0.10 (1.09)	0.05 (1.06)
Chest Pain, Week 36	Number Analyzed	85 participants	20 participants
		-0.21 (1.08)	-0.35 (1.01)
Chest Pain, Week 37	Number Analyzed	82 participants	21 participants
		-0.18 (1.18)	-0.10 (1.04)
Chest Pain, Week 38	Number Analyzed	83 participants	19 participants
		-0.32 (1.02)	-0.05 (1.01)
Chest Pain, Week 39	Number Analyzed	78 participants	18 participants
		-0.28 (0.90)	-0.22 (1.06)
Chest Pain, Week 40	Number Analyzed	76 participants	14 participants
		-0.19 (0.87)	-0.39 (0.81)
Chest Pain, Week 41	Number Analyzed	77 participants	16 participants
		-0.25 (0.93)	-0.19 (0.89)
Chest Pain, Week 42	Number Analyzed	70 participants	16 participants
		-0.16 (1.02)	-0.41 (0.74)
Chest Pain, Week 43	Number Analyzed	68 participants	16 participants
		-0.24 (0.90)	-0.22 (0.95)
Chest Pain, Week 44	Number Analyzed	76 participants	16 participants
		-0.24 (0.95)	0.00 (0.98)
Chest Pain, Week 45	Number Analyzed	69 participants	14 participants
		-0.14 (0.95)	-0.07 (0.78)
Chest Pain, Week 46	Number Analyzed	71 participants	15 participants
		-0.15 (0.94)	-0.07 (1.03)
Chest Pain, Week 47	Number Analyzed	70 participants	13 participants
		-0.22 (0.98)	-0.15 (0.90)
Chest Pain, Week 48	Number Analyzed	66 participants	11 participants
		-0.14 (0.91)	-0.18 (0.98)
Chest Pain, Week 49	Number Analyzed	65 participants	9 participants
		-0.22 (0.91)	-0.72 (0.75)
Chest Pain, Week 50	Number Analyzed	70 participants	8 participants
		-0.18 (0.91)	-0.19 (0.70)
Chest Pain, Week 51	Number Analyzed	65 participants	10 participants
		-0.13 (0.71)	-0.50 (0.78)
Chest Pain, Week 52	Number Analyzed	72 participants	7 participants
		-0.15 (0.83)	-0.36 (0.63)
Chest Pain, Week 53	Number Analyzed	64 participants	6 participants
		-0.20 (0.82)	-0.33 (0.61)
Chest Pain, Week 54	Number Analyzed	65 participants	7 participants
		-0.22 (0.87)	-0.21 (0.70)
Chest Pain, Week 55	Number Analyzed	62 participants	5 participants
		-0.34 (0.80)	-0.30 (0.76)
Chest Pain, Week 56	Number Analyzed	62 participants	6 participants
		-0.19 (0.95)	-0.33 (0.68)
Chest Pain, Week 57	Number Analyzed	62 participants	5 participants
		-0.19 (0.76)	-0.40 (0.65)
Chest Pain, Week 58	Number Analyzed	56 participants	4 participants
		-0.32 (0.92)	-0.50 (1.15)
Chest Pain, Week 59	Number Analyzed	52 participants	4 participants
		-0.25 (0.93)	-0.63 (0.75)
Chest Pain, Week 60	Number Analyzed	48 participants	4 participants
		-0.27 (1.03)	-0.50 (1.08)
Chest Pain, Week 61	Number Analyzed	49 participants	5 participants
		-0.28 (1.02)	-0.20 (1.15)
Chest Pain, Week 62	Number Analyzed	41 participants	5 participants
		-0.16 (1.06)	-0.40 (1.47)
Chest Pain, Week 63	Number Analyzed	43 participants	5 participants
		-0.12 (0.82)	-0.10 (1.34)
Chest Pain, Week 64	Number Analyzed	42 participants	4 participants
		-0.15 (0.83)	0.38 (1.44)
Chest Pain, Week 65	Number Analyzed	40 participants	3 participants
		-0.31 (0.84)	0.17 (1.76)
Chest Pain, Week 66	Number Analyzed	38 participants	4 participants
		-0.25 (0.92)	0.25 (1.19)
Chest Pain, Week 67	Number Analyzed	33 participants	4 participants
		-0.18 (0.86)	0.13 (1.44)
Chest Pain, Week 68	Number Analyzed	34 participants	4 participants
		-0.15 (0.93)	-0.25 (1.55)
Chest Pain, Week 69	Number Analyzed	35 participants	3 participants
		-0.13 (0.83)	-0.17 (1.89)
Chest Pain, Week 70	Number Analyzed	36 participants	3 participants
		-0.14 (0.93)	0.00 (1.80)
Chest Pain, Week 71	Number Analyzed	31 participants	3 participants
		-0.10 (0.88)	0.00 (0.87)
Chest Pain, Week 72	Number Analyzed	29 participants	2 participants
		-0.24 (0.85)	-1.00 (0.71)
Chest Pain, Week 73	Number Analyzed	28 participants	1 participants
		-0.25 (1.02)	-1.50
Chest Pain, Week 74	Number Analyzed	31 participants	1 participants
		-0.08 (0.93)	-1.50
Chest Pain, Week 75	Number Analyzed	31 participants	1 participants
		-0.21 (0.98)	-1.50
Chest Pain, Week 76	Number Analyzed	29 participants	1 participants
		0.03 (1.00)	-1.50
Chest Pain, Week 77	Number Analyzed	26 participants	2 participants
		-0.06 (0.89)	-1.50 (0.00)
Chest Pain, Week 78	Number Analyzed	23 participants	1 participants
		-0.04 (0.84)	-1.50
Chest Pain, Week 79	Number Analyzed	19 participants	1 participants
		-0.11 (1.09)	-0.50
Chest Pain, Week 80	Number Analyzed	20 participants	1 participants
		-0.18 (1.05)	-1.50
Chest Pain, Week 81	Number Analyzed	17 participants	1 participants
		-0.59 (0.96)	-1.50
Chest Pain, Week 82	Number Analyzed	18 participants	1 participants
		-0.39 (0.96)	-1.50
Chest Pain, Week 83	Number Analyzed	22 participants	1 participants
		-0.34 (0.90)	-1.50
Chest Pain, Week 84	Number Analyzed	20 participants	1 participants
		-0.20 (0.75)	-1.50
Chest Pain, Week 85	Number Analyzed	17 participants	1 participants
		-0.44 (0.97)	-1.50
Chest Pain, Week 86	Number Analyzed	12 participants	1 participants
		-0.38 (0.64)	-1.50
Chest Pain, Week 87	Number Analyzed	15 participants	1 participants
		-0.53 (1.01)	-1.50
Chest Pain, Week 88	Number Analyzed	14 participants	1 participants
		-0.46 (1.06)	-1.50
Chest Pain, Week 89	Number Analyzed	11 participants	1 participants
		-0.55 (0.96)	-1.50
Chest Pain, Week 90	Number Analyzed	14 participants	1 participants
		-0.18 (0.85)	-1.50
Chest Pain, Week 91	Number Analyzed	11 participants	1 participants
		-0.32 (1.08)	-1.50
Chest Pain, Week 92	Number Analyzed	10 participants	1 participants
		-0.40 (0.66)	-1.50
Chest Pain, Week 93	Number Analyzed	11 participants	1 participants
		-0.18 (1.08)	-1.50
Chest Pain, Week 94	Number Analyzed	10 participants	0 participants
		-0.30 (1.09)
Chest Pain, Week 95	Number Analyzed	10 participants	0 participants
		-0.05 (1.26)
Chest Pain, Week 96	Number Analyzed	9 participants	0 participants
		-0.17 (1.25)
Chest Pain, Week 97	Number Analyzed	8 participants	0 participants
		-0.19 (1.31)
Chest Pain, Week 98	Number Analyzed	10 participants	0 participants
		-0.25 (1.16)
Chest Pain, Week 99	Number Analyzed	7 participants	0 participants
		-0.21 (1.47)
Chest Pain, Week 100	Number Analyzed	6 participants	0 participants
		-0.50 (1.38)
Chest Pain, Week 101	Number Analyzed	7 participants	0 participants
		-0.36 (1.38)
Chest Pain, Week 102	Number Analyzed	4 participants	0 participants
		-0.75 (1.71)
Chest Pain, Week 103	Number Analyzed	6 participants	0 participants
		-0.33 (1.54)
Chest Pain, Week 104	Number Analyzed	5 participants	0 participants
		-0.60 (1.39)
Chest Pain, Week 105	Number Analyzed	4 participants	0 participants
		-1.00 (1.41)
Chest Pain, Week 106	Number Analyzed	4 participants	0 participants
		-1.00 (1.41)
Chest Pain, Week 107	Number Analyzed	4 participants	0 participants
		-1.00 (1.41)
Chest Pain, Week 108	Number Analyzed	4 participants	0 participants
		-0.75 (1.50)
Chest Pain, Week 109	Number Analyzed	5 participants	0 participants
		-0.60 (1.52)
Chest Pain, Week 110	Number Analyzed	6 participants	0 participants
		-0.42 (1.43)
Chest Pain, Week 111	Number Analyzed	5 participants	0 participants
		-0.50 (1.50)
Chest Pain, Week 112	Number Analyzed	4 participants	0 participants
		-0.13 (0.63)
Chest Pain, Week 113	Number Analyzed	4 participants	0 participants
		0.13 (0.63)
Chest Pain, Week 114	Number Analyzed	3 participants	0 participants
		0.00 (1.00)
Chest Pain, Week 115	Number Analyzed	2 participants	0 participants
		0.25 (0.35)
Chest Pain, Week 116	Number Analyzed	2 participants	0 participants
		0.50 (0.71)
Chest Pain, Week 117	Number Analyzed	2 participants	0 participants
		0.25 (1.06)
Chest Pain, Week 118	Number Analyzed	2 participants	0 participants
		-0.25 (1.06)
Chest Pain, Week 119	Number Analyzed	2 participants	0 participants
		-0.25 (0.35)
Chest Pain, Week 120	Number Analyzed	2 participants	0 participants
		0.00 (0.71)
Chest Pain, Week 121	Number Analyzed	2 participants	0 participants
		0.00 (1.41)
Chest Pain, Week 122	Number Analyzed	2 participants	0 participants
		0.00 (1.41)
Chest Pain, Week 123	Number Analyzed	2 participants	0 participants
		-0.75 (1.77)
Chest Pain, Week 124	Number Analyzed	1 participants	0 participants
		0.50
Chest Pain, Week 125	Number Analyzed	1 participants	0 participants
		0.50
Chest Pain, Survival Follow-Up Month 1	Number Analyzed	158 participants	58 participants
		0.01 (1.13)	0.22 (0.87)
Chest Pain, Survival Follow-Up Month 2	Number Analyzed	42 participants	47 participants
		-0.07 (1.18)	-0.16 (0.96)
Chest Pain, Survival Follow-Up Month 3	Number Analyzed	36 participants	26 participants
		0.15 (1.33)	-0.08 (0.87)
Chest Pain, Survival Follow-Up Month 4	Number Analyzed	23 participants	28 participants
		-0.28 (1.40)	-0.07 (0.79)
Chest Pain, Survival Follow-Up Month 5	Number Analyzed	22 participants	22 participants
		-0.11 (1.49)	-0.02 (0.65)
Chest Pain, Survival Follow-Up Month 6	Number Analyzed	15 participants	21 participants
		-0.37 (1.67)	0.02 (0.78)
Cough, Week 1	Number Analyzed	203 participants	114 participants
		0.08 (0.69)	0.04 (0.73)
Cough, Week 2	Number Analyzed	204 participants	108 participants
		0.02 (0.78)	0.04 (0.84)
Cough, Week 3	Number Analyzed	197 participants	106 participants
		0.02 (0.86)	-0.09 (0.93)
Cough, Week 4	Number Analyzed	190 participants	102 participants
		-0.06 (0.86)	-0.10 (0.93)
Cough, Week 5	Number Analyzed	192 participants	97 participants
		-0.09 (0.84)	-0.09 (0.99)
Cough, Week 6	Number Analyzed	182 participants	98 participants
		-0.15 (0.86)	-0.08 (0.98)
Cough, Week 7	Number Analyzed	176 participants	87 participants
		-0.11 (0.86)	-0.06 (1.01)
Cough, Week 8	Number Analyzed	169 participants	80 participants
		-0.13 (0.95)	-0.21 (1.04)
Cough, Week 9	Number Analyzed	172 participants	80 participants
		-0.15 (0.99)	-0.13 (1.23)
Cough, Week 10	Number Analyzed	166 participants	75 participants
		-0.20 (1.05)	-0.07 (1.17)
Cough, Week 11	Number Analyzed	171 participants	78 participants
		-0.15 (1.03)	-0.15 (1.17)
Cough, Week 12	Number Analyzed	160 participants	72 participants
		-0.17 (1.03)	-0.11 (1.09)
Cough, Week 13	Number Analyzed	151 participants	61 participants
		-0.24 (1.08)	-0.04 (1.11)
Cough, Week 14	Number Analyzed	144 participants	62 participants
		-0.23 (1.06)	-0.18 (1.08)
Cough, Week 15	Number Analyzed	143 participants	51 participants
		-0.27 (1.06)	-0.05 (1.10)
Cough, Week 16	Number Analyzed	139 participants	52 participants
		-0.37 (1.07)	-0.25 (1.09)
Cough, Week 17	Number Analyzed	145 participants	53 participants
		-0.32 (1.09)	-0.21 (1.01)
Cough, Week 18	Number Analyzed	136 participants	49 participants
		-0.33 (1.07)	-0.33 (1.09)
Cough, Week 19	Number Analyzed	124 participants	45 participants
		-0.33 (1.06)	-0.40 (0.89)
Cough, Week 20	Number Analyzed	123 participants	43 participants
		-0.37 (1.10)	-0.31 (0.90)
Cough, Week 21	Number Analyzed	126 participants	41 participants
		-0.37 (1.08)	-0.33 (0.96)
Cough, Week 22	Number Analyzed	116 participants	37 participants
		-0.37 (1.15)	-0.24 (0.97)
Cough, Week 23	Number Analyzed	122 participants	35 participants
		-0.30 (1.10)	-0.41 (1.03)
Cough, Week 24	Number Analyzed	110 participants	34 participants
		-0.38 (1.09)	-0.54 (1.04)
Cough, Week 25	Number Analyzed	104 participants	31 participants
		-0.49 (0.91)	-0.47 (1.05)
Cough, Week 26	Number Analyzed	109 participants	31 participants
		-0.43 (0.99)	-0.34 (1.02)
Cough, Week 27	Number Analyzed	102 participants	27 participants
		-0.41 (0.97)	-0.48 (0.98)
Cough, Week 28	Number Analyzed	96 participants	28 participants
		-0.52 (0.96)	-0.43 (0.84)
Cough, Week 29	Number Analyzed	104 participants	27 participants
		-0.43 (0.98)	-0.46 (0.91)
Cough, Week 30	Number Analyzed	100 participants	23 participants
		-0.43 (0.95)	-0.46 (1.07)
Cough, Week 31	Number Analyzed	93 participants	25 participants
		-0.32 (1.07)	-0.38 (0.77)
Cough, Week 32	Number Analyzed	88 participants	25 participants
		-0.30 (0.94)	-0.12 (0.99)
Cough, Week 33	Number Analyzed	88 participants	25 participants
		-0.19 (1.12)	-0.52 (1.03)
Cough, Week 34	Number Analyzed	85 participants	24 participants
		-0.35 (1.12)	-0.33 (1.03)
Cough, Week 35	Number Analyzed	87 participants	20 participants
		-0.46 (1.01)	0.00 (1.22)
Cough, Week 36	Number Analyzed	85 participants	20 participants
		-0.35 (1.08)	-0.20 (1.01)
Cough, Week 37	Number Analyzed	82 participants	21 participants
		-0.46 (1.03)	-0.45 (1.11)
Cough, Week 38	Number Analyzed	83 participants	19 participants
		-0.38 (1.06)	-0.03 (0.89)
Cough, Week 39	Number Analyzed	78 participants	18 participants
		-0.27 (0.99)	-0.17 (1.00)
Cough, Week 40	Number Analyzed	76 participants	14 participants
		-0.38 (0.95)	-0.50 (0.90)
Cough, Week 41	Number Analyzed	77 participants	16 participants
		-0.44 (0.92)	-0.22 (0.77)
Cough, Week 42	Number Analyzed	70 participants	16 participants
		-0.44 (0.92)	-0.41 (0.97)
Cough, Week 43	Number Analyzed	68 participants	16 participants
		-0.39 (0.98)	-0.13 (0.92)
Cough, Week 44	Number Analyzed	76 participants	16 participants
		-0.38 (0.94)	-0.16 (0.89)
Cough, Week 45	Number Analyzed	69 participants	14 participants
		-0.30 (1.10)	-0.14 (1.03)
Cough, Week 46	Number Analyzed	71 participants	15 participants
		-0.25 (0.99)	-0.03 (1.23)
Cough, Week 47	Number Analyzed	70 participants	13 participants
		-0.44 (0.88)	-0.12 (1.23)
Cough, Week 48	Number Analyzed	66 participants	11 participants
		-0.29 (0.99)	0.14 (1.21)
Cough, Week 49	Number Analyzed	65 participants	9 participants
		-0.38 (1.00)	-0.56 (1.36)
Cough, Week 50	Number Analyzed	70 participants	8 participants
		-0.39 (0.96)	-0.19 (1.16)
Cough, Week 51	Number Analyzed	65 participants	10 participants
		-0.30 (1.00)	-0.40 (1.20)
Cough, Week 52	Number Analyzed	72 participants	7 participants
		-0.32 (1.03)	-0.21 (1.07)
Cough, Week 53	Number Analyzed	64 participants	6 participants
		-0.37 (1.03)	-0.17 (1.33)
Cough, Week 54	Number Analyzed	65 participants	7 participants
		-0.41 (0.93)	-0.07 (1.21)
Cough, Week 55	Number Analyzed	62 participants	5 participants
		-0.40 (0.93)	0.10 (1.34)
Cough, Week 56	Number Analyzed	62 participants	6 participants
		-0.26 (0.94)	0.17 (1.13)
Cough, Week 57	Number Analyzed	62 participants	5 participants
		-0.35 (0.98)	0.00 (1.27)
Cough, Week 58	Number Analyzed	56 participants	4 participants
		-0.33 (1.06)	0.13 (1.31)
Cough, Week 59	Number Analyzed	52 participants	4 participants
		-0.31 (0.97)	0.13 (1.60)
Cough, Week 60	Number Analyzed	48 participants	4 participants
		-0.42 (0.89)	0.38 (1.18)
Cough, Week 61	Number Analyzed	49 participants	5 participants
		-0.35 (0.95)	0.80 (1.20)
Cough, Week 62	Number Analyzed	41 participants	5 participants
		-0.23 (1.03)	0.50 (1.62)
Cough, Week 63	Number Analyzed	43 participants	5 participants
		-0.22 (1.04)	0.50 (1.27)
Cough, Week 64	Number Analyzed	42 participants	4 participants
		-0.19 (1.07)	0.00 (1.87)
Cough, Week 65	Number Analyzed	40 participants	3 participants
		-0.23 (1.04)	0.83 (1.04)
Cough, Week 66	Number Analyzed	38 participants	4 participants
		-0.29 (0.90)	0.63 (1.03)
Cough, Week 67	Number Analyzed	33 participants	4 participants
		-0.48 (0.91)	0.38 (1.38)
Cough, Week 68	Number Analyzed	34 participants	4 participants
		-0.34 (0.82)	0.13 (1.49)
Cough, Week 69	Number Analyzed	35 participants	3 participants
		-0.34 (1.03)	0.17 (1.61)
Cough, Week 70	Number Analyzed	36 participants	3 participants
		-0.26 (0.94)	0.17 (1.61)
Cough, Week 71	Number Analyzed	31 participants	3 participants
		-0.23 (0.91)	0.33 (1.04)
Cough, Week 72	Number Analyzed	29 participants	2 participants
		-0.48 (0.87)	-1.50 (1.41)
Cough, Week 73	Number Analyzed	28 participants	1 participants
		-0.43 (0.91)	-0.50
Cough, Week 74	Number Analyzed	31 participants	1 participants
		-0.42 (0.93)	-0.50
Cough, Week 75	Number Analyzed	31 participants	1 participants
		-0.32 (1.00)	-0.50
Cough, Week 76	Number Analyzed	29 participants	1 participants
		-0.31 (0.91)	-0.50
Cough, Week 77	Number Analyzed	26 participants	2 participants
		-0.40 (0.92)	-0.50 (2.83)
Cough, Week 78	Number Analyzed	23 participants	1 participants
		-0.52 (0.94)	0.00
Cough, Week 79	Number Analyzed	19 participants	1 participants
		-0.08 (0.93)	1.00
Cough, Week 80	Number Analyzed	20 participants	1 participants
		-0.48 (0.87)	1.00
Cough, Week 81	Number Analyzed	17 participants	1 participants
		-0.44 (1.01)	-0.50
Cough, Week 82	Number Analyzed	18 participants	1 participants
		-0.39 (0.90)	1.00
Cough, Week 83	Number Analyzed	22 participants	1 participants
		-0.25 (1.09)	0.50
Cough, Week 84	Number Analyzed	20 participants	1 participants
		-0.30 (0.91)	1.00
Cough, Week 85	Number Analyzed	17 participants	1 participants
		-0.32 (1.25)	1.50
Cough, Week 86	Number Analyzed	12 participants	1 participants
		-0.54 (1.27)	0.00
Cough, Week 87	Number Analyzed	15 participants	1 participants
		-0.33 (1.18)	0.00
Cough, Week 88	Number Analyzed	14 participants	1 participants
		-0.46 (1.26)	0.00
Cough, Week 89	Number Analyzed	11 participants	1 participants
		-0.36 (1.07)	0.00
Cough, Week 90	Number Analyzed	14 participants	1 participants
		-0.29 (1.05)	0.00
Cough, Week 91	Number Analyzed	11 participants	1 participants
		-0.27 (1.17)	0.00
Cough, Week 92	Number Analyzed	10 participants	1 participants
		-0.35 (1.27)	1.00
Cough, Week 93	Number Analyzed	11 participants	1 participants
		-0.55 (0.96)	0.00
Cough, Week 94	Number Analyzed	10 participants	0 participants
		-0.40 (0.81)
Cough, Week 95	Number Analyzed	10 participants	0 participants
		0.05 (1.23)
Cough, Week 96	Number Analyzed	9 participants	0 participants
		-0.28 (1.28)
Cough, Week 97	Number Analyzed	8 participants	0 participants
		-0.31 (1.19)
Cough, Week 98	Number Analyzed	10 participants	0 participants
		-0.10 (0.99)
Cough, Week 99	Number Analyzed	7 participants	0 participants
		-0.43 (0.98)
Cough, Week 100	Number Analyzed	6 participants	0 participants
		-0.58 (0.86)
Cough, Week 101	Number Analyzed	7 participants	0 participants
		-0.50 (0.96)
Cough, Week 102	Number Analyzed	4 participants	0 participants
		-0.50 (0.41)
Cough, Week 103	Number Analyzed	6 participants	0 participants
		-0.75 (0.42)
Cough, Week 104	Number Analyzed	5 participants	0 participants
		-0.80 (0.27)
Cough, Week 105	Number Analyzed	4 participants	0 participants
		-0.63 (0.48)
Cough, Week 106	Number Analyzed	4 participants	0 participants
		-0.63 (0.48)
Cough, Week 107	Number Analyzed	4 participants	0 participants
		-0.63 (0.48)
Cough, Week 108	Number Analyzed	4 participants	0 participants
		-0.50 (0.71)
Cough, Week 109	Number Analyzed	5 participants	0 participants
		-0.50 (0.50)
Cough, Week 110	Number Analyzed	6 participants	0 participants
		-0.50 (0.45)
Cough, Week 111	Number Analyzed	5 participants	0 participants
		-0.30 (0.84)
Cough, Week 112	Number Analyzed	4 participants	0 participants
		-0.63 (0.48)
Cough, Week 113	Number Analyzed	4 participants	0 participants
		-0.25 (0.65)
Cough, Week 114	Number Analyzed	3 participants	0 participants
		-0.33 (0.29)
Cough, Week 115	Number Analyzed	2 participants	0 participants
		0.25 (0.35)
Cough, Week 116	Number Analyzed	2 participants	0 participants
		-0.25 (1.06)
Cough, Week 117	Number Analyzed	2 participants	0 participants
		-0.50 (0.71)
Cough, Week 118	Number Analyzed	2 participants	0 participants
		-0.25 (0.35)
Cough, Week 119	Number Analyzed	2 participants	0 participants
		0.00 (0.00)
Cough, Week 120	Number Analyzed	2 participants	0 participants
		-0.25 (0.35)
Cough, Week 121	Number Analyzed	2 participants	0 participants
		-0.50 (0.71)
Cough, Week 122	Number Analyzed	2 participants	0 participants
		-0.50 (0.71)
Cough, Week 123	Number Analyzed	2 participants	0 participants
		-0.75 (1.06)
Cough, Week 124	Number Analyzed	1 participants	0 participants
		0.50
Cough, Week 125	Number Analyzed	1 participants	0 participants
		0.50
Cough, Survival Follow-Up Month 1	Number Analyzed	158 participants	58 participants
		-0.21 (1.05)	-0.01 (0.96)
Cough, Survival Follow-Up Month 2	Number Analyzed	42 participants	47 participants
		-0.07 (1.16)	-0.31 (1.18)
Cough, Survival Follow-Up Month 3	Number Analyzed	36 participants	26 participants
		-0.14 (1.12)	-0.13 (1.32)
Cough, Survival Follow-Up Month 4	Number Analyzed	23 participants	28 participants
		-0.39 (1.15)	-0.45 (1.17)
Cough, Survival Follow-Up Month 5	Number Analyzed	22 participants	22 participants
		-0.25 (1.44)	-0.27 (1.32)
Cough, Survival Follow-Up Month 6	Number Analyzed	15 participants	21 participants
		-0.23 (1.53)	-0.29 (1.26)
Dyspnoea, Week 1	Number Analyzed	203 participants	114 participants
		0.13 (0.76)	0.23 (0.79)
Dyspnoea, Week 2	Number Analyzed	204 participants	108 participants
		0.10 (0.68)	0.31 (0.84)
Dyspnoea, Week 3	Number Analyzed	197 participants	106 participants
		0.22 (0.78)	0.32 (0.76)
Dyspnoea, Week 4	Number Analyzed	190 participants	102 participants
		0.23 (0.80)	0.45 (0.84)
Dyspnoea, Week 5	Number Analyzed	192 participants	97 participants
		0.26 (0.84)	0.42 (0.92)
Dyspnoea, Week 6	Number Analyzed	182 participants	96 participants
		0.27 (0.92)	0.51 (0.95)
Dyspnoea, Week 7	Number Analyzed	176 participants	87 participants
		0.29 (0.88)	0.60 (1.00)
Dyspnoea, Week 8	Number Analyzed	169 participants	80 participants
		0.32 (0.97)	0.53 (1.02)
Dyspnoea, Week 9	Number Analyzed	172 participants	80 participants
		0.38 (0.95)	0.62 (1.07)
Dyspnoea, Week 10	Number Analyzed	166 participants	75 participants
		0.41 (1.04)	0.75 (1.13)
Dyspnoea, Week 11	Number Analyzed	171 participants	78 participants
		0.50 (1.05)	0.60 (1.06)
Dyspnoea, Week 12	Number Analyzed	160 participants	72 participants
		0.47 (1.07)	0.74 (1.08)
Dyspnoea, Week 13	Number Analyzed	151 participants	61 participants
		0.32 (1.00)	0.76 (1.00)
Dyspnoea, Week 14	Number Analyzed	144 participants	62 participants
		0.34 (0.99)	0.61 (1.10)
Dyspnoea, Week 15	Number Analyzed	143 participants	51 participants
		0.29 (1.06)	0.71 (1.02)
Dyspnoea, Week 16	Number Analyzed	139 participants	52 participants
		0.22 (0.99)	0.67 (1.11)
Dyspnoea, Week 17	Number Analyzed	145 participants	53 participants
		0.28 (1.10)	0.68 (1.03)
Dyspnoea, Week 18	Number Analyzed	136 participants	49 participants
		0.23 (1.02)	0.62 (1.03)
Dyspnoea, Week 19	Number Analyzed	124 participants	45 participants
		0.26 (1.06)	0.54 (0.95)
Dyspnoea, Week 20	Number Analyzed	123 participants	43 participants
		0.24 (1.02)	0.54 (1.08)
Dyspnoea, Week 21	Number Analyzed	126 participants	41 participants
		0.26 (1.04)	0.39 (1.05)
Dyspnoea, Week 22	Number Analyzed	116 participants	37 participants
		0.21 (0.94)	0.41 (1.05)
Dyspnoea, Week 23	Number Analyzed	122 participants	35 participants
		0.18 (0.97)	0.41 (1.06)
Dyspnoea, Week 24	Number Analyzed	110 participants	34 participants
		0.22 (0.93)	0.31 (1.01)
Dyspnoea, Week 25	Number Analyzed	104 participants	31 participants
		0.21 (0.88)	0.20 (0.91)
Dyspnoea, Week 26	Number Analyzed	109 participants	31 participants
		0.17 (0.89)	0.30 (1.00)
Dyspnoea, Week 27	Number Analyzed	102 participants	27 participants
		0.20 (1.04)	0.30 (0.92)
Dyspnoea, Week 28	Number Analyzed	96 participants	28 participants
		0.16 (0.94)	0.22 (1.01)
Dyspnoea, Week 29	Number Analyzed	104 participants	27 participants
		0.16 (0.92)	0.33 (0.98)
Dyspnoea, Week 30	Number Analyzed	100 participants	23 participants
		0.24 (1.04)	0.27 (1.02)
Dyspnoea, Week 31	Number Analyzed	93 participants	25 participants
		0.12 (0.99)	0.26 (1.04)
Dyspnoea, Week 32	Number Analyzed	88 participants	25 participants
		0.20 (0.95)	0.38 (1.06)
Dyspnoea, Week 33	Number Analyzed	88 participants	25 participants
		0.18 (0.98)	0.19 (1.14)
Dyspnoea, Week 34	Number Analyzed	85 participants	24 participants
		0.21 (1.06)	0.30 (1.02)
Dyspnoea, Week 35	Number Analyzed	87 participants	20 participants
		0.22 (1.03)	0.46 (0.96)
Dyspnoea, Week 36	Number Analyzed	85 participants	20 participants
		0.21 (1.09)	0.34 (1.14)
Dyspnoea, Week 37	Number Analyzed	82 participants	21 participants
		0.16 (1.13)	0.10 (1.07)
Dyspnoea, Week 38	Number Analyzed	83 participants	19 participants
		0.18 (1.07)	0.51 (0.99)
Dyspnoea, Week 39	Number Analyzed	78 participants	18 participants
		0.31 (1.04)	0.26 (0.83)
Dyspnoea, Week 40	Number Analyzed	76 participants	14 participants
		0.31 (0.99)	0.04 (0.79)
Dyspnoea, Week 41	Number Analyzed	77 participants	16 participants
		0.24 (0.99)	0.18 (0.85)
Dyspnoea, Week 42	Number Analyzed	70 participants	16 participants
		0.26 (1.03)	0.08 (0.70)
Dyspnoea, Week 43	Number Analyzed	68 participants	16 participants
		0.17 (1.13)	0.41 (0.91)
Dyspnoea, Week 44	Number Analyzed	76 participants	16 participants
		0.22 (1.06)	0.29 (0.86)
Dyspnoea, Week 45	Number Analyzed	69 participants	14 participants
		0.26 (1.09)	0.31 (0.90)
Dyspnoea, Week 46	Number Analyzed	71 participants	15 participants
		0.29 (0.99)	0.47 (1.03)
Dyspnoea, Week 47	Number Analyzed	70 participants	13 participants
		0.20 (1.02)	0.45 (0.85)
Dyspnoea, Week 48	Number Analyzed	66 participants	11 participants
		0.32 (1.00)	0.29 (0.91)
Dyspnoea, Week 49	Number Analyzed	65 participants	9 participants
		0.24 (1.04)	0.00 (1.30)
Dyspnoea, Week 50	Number Analyzed	70 participants	8 participants
		0.32 (0.98)	0.43 (0.88)
Dyspnoea, Week 51	Number Analyzed	65 participants	10 participants
		0.24 (0.92)	0.06 (1.04)
Dyspnoea, Week 52	Number Analyzed	72 participants	7 participants
		0.27 (0.95)	0.29 (0.90)
Dyspnoea, Week 53	Number Analyzed	64 participants	6 participants
		0.24 (1.00)	0.30 (0.85)
Dyspnoea, Week 54	Number Analyzed	65 participants	7 participants
		0.28 (0.89)	0.40 (0.95)
Dyspnoea, Week 55	Number Analyzed	62 participants	5 participants
		0.26 (0.98)	0.44 (1.02)
Dyspnoea, Week 56	Number Analyzed	62 participants	6 participants
		0.26 (0.97)	0.53 (1.10)
Dyspnoea, Week 57	Number Analyzed	62 participants	5 participants
		0.37 (0.95)	0.24 (1.08)
Dyspnoea, Week 58	Number Analyzed	56 participants	4 participants
		0.19 (1.01)	0.35 (1.40)
Dyspnoea, Week 59	Number Analyzed	52 participants	4 participants
		0.32 (0.84)	0.35 (1.40)
Dyspnoea, Week 60	Number Analyzed	48 participants	4 participants
		0.35 (0.99)	0.50 (1.51)
Dyspnoea, Week 61	Number Analyzed	49 participants	5 participants
		0.33 (1.03)	0.60 (1.40)
Dyspnoea, Week 62	Number Analyzed	41 participants	5 participants
		0.45 (0.99)	0.72 (1.36)
Dyspnoea, Week 63	Number Analyzed	43 participants	5 participants
		0.44 (1.05)	0.56 (1.35)
Dyspnoea, Week 64	Number Analyzed	42 participants	4 participants
		0.36 (0.98)	-0.50 (1.91)
Dyspnoea, Week 65	Number Analyzed	40 participants	3 participants
		0.27 (0.97)	0.07 (1.68)
Dyspnoea, Week 66	Number Analyzed	38 participants	4 participants
		0.32 (1.11)	0.50 (1.23)
Dyspnoea, Week 67	Number Analyzed	33 participants	4 participants
		0.28 (0.91)	0.40 (1.36)
Dyspnoea, Week 68	Number Analyzed	34 participants	4 participants
		0.35 (0.96)	0.40 (1.43)
Dyspnoea, Week 69	Number Analyzed	35 participants	3 participants
		0.44 (1.02)	0.73 (1.55)
Dyspnoea, Week 70	Number Analyzed	36 participants	3 participants
		0.33 (0.97)	0.73 (1.55)
Dyspnoea, Week 71	Number Analyzed	31 participants	3 participants
		0.50 (0.95)	0.60 (1.51)
Dyspnoea, Week 72	Number Analyzed	29 participants	3 participants
		0.17 (0.95)	0.60 (1.44)
Dyspnoea, Week 73	Number Analyzed	28 participants	2 participants
		0.41 (0.96)	-1.80 (1.13)
Dyspnoea, Week 74	Number Analyzed	31 participants	1 participants
		0.30 (1.00)	-1.00
Dyspnoea, Week 75	Number Analyzed	31 participants	1 participants
		0.26 (0.89)	-1.00
Dyspnoea, Week 76	Number Analyzed	29 participants	1 participants
		0.23 (0.89)	-1.00
Dyspnoea, Week 77	Number Analyzed	26 participants	2 participants
		0.20 (0.97)	-1.50 (1.56)
Dyspnoea, Week 78	Number Analyzed	23 participants	1 participants
		0.31 (0.94)	-1.00
Dyspnoea, Week 79	Number Analyzed	19 participants	1 participants
		0.32 (0.95)	-1.00
Dyspnoea, Week 80	Number Analyzed	20 participants	1 participants
		0.30 (0.92)	-1.00
Dyspnoea, Week 81	Number Analyzed	17 participants	1 participants
		-0.12 (1.00)	-0.80
Dyspnoea, Week 82	Number Analyzed	18 participants	1 participants
		0.02 (1.06)	-0.80
Dyspnoea, Week 83	Number Analyzed	22 participants	1 participants
		0.13 (1.01)	-1.00
Dyspnoea, Week 84	Number Analyzed	20 participants	1 participants
		0.19 (1.00)	-1.00
Dyspnoea, Week 85	Number Analyzed	17 participants	1 participants
		0.05 (1.17)	-0.80
Dyspnoea, Week 86	Number Analyzed	12 participants	1 participants
		-0.07 (1.05)	-1.00
Dyspnoea, Week 87	Number Analyzed	15 participants	1 participants
		-0.11 (0.96)	-1.00
Dyspnoea, Week 88	Number Analyzed	14 participants	1 participants
		0.06 (1.12)	-1.00
Dyspnoea, Week 89	Number Analyzed	11 participants	1 participants
		0.09 (0.91)	-1.00
Dyspnoea, Week 90	Number Analyzed	14 participants	1 participants
		0.37 (0.83)	-1.00
Dyspnoea, Week 91	Number Analyzed	11 participants	1 participants
		0.33 (1.11)	-1.00
Dyspnoea, Week 92	Number Analyzed	10 participants	1 participants
		0.20 (1.05)	-0.80
Dyspnoea, Week 93	Number Analyzed	11 participants	1 participants
		0.35 (0.96)	-0.80
Dyspnoea, Week 94	Number Analyzed	10 participants	0 participants
		0.50 (0.93)
Dyspnoea, Week 95	Number Analyzed	10 participants	0 participants
		0.48 (0.98)
Dyspnoea, Week 96	Number Analyzed	9 participants	0 participants
		0.51 (1.09)
Dyspnoea, Week 97	Number Analyzed	8 participants	0 participants
		0.33 (1.18)
Dyspnoea, Week 98	Number Analyzed	10 participants	0 participants
		0.38 (1.05)
Dyspnoea, Week 99	Number Analyzed	7 participants	0 participants
		0.11 (0.99)
Dyspnoea, Week 100	Number Analyzed	6 participants	0 participants
		0.27 (1.11)
Dyspnoea, Week 101	Number Analyzed	7 participants	0 participants
		0.20 (1.11)
Dyspnoea, Week 102	Number Analyzed	4 participants	0 participants
		0.35 (1.06)
Dyspnoea, Week 103	Number Analyzed	6 participants	0 participants
		0.47 (1.29)
Dyspnoea, Week 104	Number Analyzed	5 participants	0 participants
		0.48 (1.22)
Dyspnoea, Week 105	Number Analyzed	4 participants	0 participants
		-0.20 (0.71)
Dyspnoea, Week 106	Number Analyzed	4 participants	0 participants
		-0.20 (0.99)
Dyspnoea, Week 107	Number Analyzed	4 participants	0 participants
		-0.30 (0.62)
Dyspnoea, Week 108	Number Analyzed	4 participants	0 participants
		-0.15 (0.98)
Dyspnoea, Week 109	Number Analyzed	5 participants	0 participants
		0.16 (1.17)
Dyspnoea, Week 110	Number Analyzed	6 participants	0 participants
		0.33 (1.00)
Dyspnoea, Week 111	Number Analyzed	5 participants	0 participants
		-0.04 (0.86)
Dyspnoea, Week 112	Number Analyzed	4 participants	0 participants
		0.20 (0.43)
Dyspnoea, Week 113	Number Analyzed	4 participants	0 participants
		0.20 (0.67)
Dyspnoea, Week 114	Number Analyzed	3 participants	0 participants
		0.40 (0.72)
Dyspnoea, Week 115	Number Analyzed	2 participants	0 participants
		0.80 (0.85)
Dyspnoea, Week 116	Number Analyzed	2 participants	0 participants
		0.60 (0.57)
Dyspnoea, Week 117	Number Analyzed	2 participants	0 participants
		0.30 (0.14)
Dyspnoea, Week 118	Number Analyzed	2 participants	0 participants
		0.30 (0.42)
Dyspnoea, Week 119	Number Analyzed	2 participants	0 participants
		0.50 (0.42)
Dyspnoea, Week 120	Number Analyzed	2 participants	0 participants
		0.30 (0.42)
Dyspnoea, Week 121	Number Analyzed	2 participants	0 participants
		0.60 (0.57)
Dyspnoea, Week 122	Number Analyzed	2 participants	0 participants
		0.60 (0.00)
Dyspnoea, Week 123	Number Analyzed	2 participants	0 participants
		-0.20 (0.57)
Dyspnoea, Week 124	Number Analyzed	1 participants	0 participants
		-0.20
Dyspnoea, Week 125	Number Analyzed	1 participants	0 participants
		0.20
Dyspnoea, Survival Follow-Up Month 1	Number Analyzed	158 participants	58 participants
		0.41 (1.11)	0.60 (1.14)
Dyspnoea, Survival Follow-Up Month 2	Number Analyzed	42 participants	47 participants
		0.36 (1.20)	0.46 (1.22)
Dyspnoea, Survival Follow-Up Month 3	Number Analyzed	36 participants	26 participants
		0.27 (0.96)	0.61 (1.19)
Dyspnoea, Survival Follow-Up Month 4	Number Analyzed	23 participants	28 participants
		0.02 (1.11)	0.45 (0.88)
Dyspnoea, Survival Follow-Up Month 5	Number Analyzed	22 participants	22 participants
		0.13 (1.24)	0.48 (1.00)
Dyspnoea, Survival Follow-Up Month 6	Number Analyzed	15 participants	21 participants
		-0.09 (1.29)	0.54 (0.97)

13. Secondary Outcome

Title	Percentage of Participants With Adverse Events
Description	Percentage of participants with at least one adverse event. Adverse event onset date before cross over.
Time Frame	Up to approximately 69 months after first patient enrolled

Outcome Measure Data

Analysis Population Description

The safety-evaluable population included all treated participants, defined as randomized participants who received any protocol treatment. For the safety analyses, participants were grouped according to whether any full or partial dose of atezolizumab was received, including when atezolizumab was received in error. Specifically, for participants randomized to the CnP arm, if atezolizumab was received in error, the participants were grouped to the Atezo+CnP arm for the safety analyses.

Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed	473	232
Measure Type: Number; Unit of Measure: Percentage of participants
	99.6	98.7

14. Secondary Outcome

Title	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Description	Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B Carboplatin+nab-paclitaxel Crossover Participants
Time Frame	Up to approximately 35 months after first subject enrolled

Outcome Measure Data

Analysis Population Description

The baseline ADA-evaluable population included participants who had a baseline ADA result. The post-baseline ADA-evaluable population included participants who had at least one post-baseline ADA result and who had received at least one dose of study treatment. The ADA-evaluable WT population was defined as the ADA-evaluable population excluding participants with an activating EGFR mutation or ALK translocation.

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		473	96
Measure Type: Number; Unit of Measure: Perecentage of participants
Baseline	Number Analyzed	473 participants	84 participants
		3.1	4.8
Post-baseline	Number Analyzed	446 participants	96 participants
		22.4	23.5

15. Secondary Outcome

Title	Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm
Description	Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.
Time Frame	Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)

Outcome Measure Data

Analysis Population Description

The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
Overall Number of Participants Analyzed		465
Mean (Standard Deviation); Unit of Measure: mcg/mL
Cycle 1 Day 1	Number Analyzed	437 participants
		392 (114)
Cycle 3 Day 1	Number Analyzed	356 participants
		454 (170)

16. Secondary Outcome

Title	Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel
Description	Predose samples will be collected on the same day of treatment administration.
Time Frame	Cycle 1 Day 21, Cycle 2 Day 21, Cycle 3 Day 21, and Cycle 7 Day 21 (Cycle length = 21 days)

Outcome Measure Data

Analysis Population Description

The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
Overall Number of Participants Analyzed		465
Mean (Standard Deviation); Unit of Measure: mcg/mL
Cycle 1 Day 21	Number Analyzed	416 participants
		70.9 (35.1)
Cycle 2 Day 21	Number Analyzed	384 participants
		111 (52.2)
Cycle 3 Day 21	Number Analyzed	352 participants
		134 (57.8)
Cycle 7 Day 21	Number Analyzed	257 participants
		218 (93.7)

17. Secondary Outcome

Title	Plasma Concentrations of Carboplatin
Description	[Not Specified]
Time Frame	Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 hour after carboplatin infusion (infusion duration=15 to 30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)

Outcome Measure Data

Analysis Population Description

The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin Crossover)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		29	20
Mean (Standard Deviation); Unit of Measure: ng/mL
Cycle 1 Day 1 Pre-dose	Number Analyzed	29 participants	19 participants
		NA [1] (NA)	NA [1] (NA)
Cycle 1 Day 1 Before End of Infusion	Number Analyzed	23 participants	18 participants
		20,500 (7500)	17,000 (5200)
Cycle 1 Day 1 Post Infusion	Number Analyzed	29 participants	18 participants
		11,900 (3100)	12,400 (3800)
Cycle 3 Day 1 Pre-dose	Number Analyzed	23 participants	16 participants
		169 (63.8)	160 (48.8)
Cycle 3 Day 1 Before End of Infusion	Number Analyzed	16 participants	14 participants
		15,300 (6600)	17,800 (7550)
Cycle 3 Day 1 Post Infusion	Number Analyzed	18 participants	15 participants
		11,400 (3060)	13,400 (6650)

[1]

Below the level of detection.

18. Secondary Outcome

Title	Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel
Description	[Not Specified]
Time Frame	Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after nab-paclitaxel infusion (infusion duration=30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)

Outcome Measure Data

Analysis Population Description

The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.

Arm/Group Title		Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	Arm B (Nab-Paclitaxel+Carboplatin Crossover)
Arm/Group Description:		Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.	Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Overall Number of Participants Analyzed		30	20
Mean (Standard Deviation); Unit of Measure: ng/mL
Cycle 1 Day 1 Pre-dose	Number Analyzed	29 participants	19 participants
		NA [1] (NA)	NA [1] (NA)
Cycle 1 Day 1 Before End of Infusion	Number Analyzed	27 participants	15 participants
		3520 (2210)	2530 (1420)
Cycle 1 Day 1 Post Infusion	Number Analyzed	25 participants	17 participants
		307 (153)	417 (217)
Cycle 3 Day 1 Pre-dose	Number Analyzed	23 participants	16 participants
		NA [2] (NA)	NA [2] (NA)
Cycle 3 Day 1 Before End of Infusion	Number Analyzed	17 participants	10 participants
		4480 (3520)	2030 (1690)
Cycle 3 Day 1 Post Infusion	Number Analyzed	18 participants	15 participants
		357 (253)	447 (322)

[1]

Below the level of detection.

[2]

Below the threshold of the assay.

Adverse Events

Time Frame	From the first study drug to the data cutoff date: 18 January 2021 (approximately 69 months)
Adverse Event Reporting Description	The safety-evaluable population included all treated participants, defined as randomized participants who received any protocol treatment. For the safety analyses, participants were grouped according to whether any full or partial dose of atezolizumab was received, including when atezolizumab was received in error. Specifically, for participants randomized to the CnP arm, if atezolizumab was received in error, the participants were grouped to the Atezo+CnP arm for the safety analyses.
Arm/Group Title	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)		Arm B Without Crossover Participants (Nab-Paclitaxel+Carboplatin)		Arm B With Crossover Participants (Nab-Paclitaxel+Carboplatin, After Crossover Atezo Monotherapy)
Arm/Group Description	Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.		Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression. This Arm B group includes participants who did not crossover to receive atezolizumab as monotherapy.		Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression. This Arm B group includes participants who crossed over to receive atezolizumab as monotherapy.
All-Cause Mortality
	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)		Arm B Without Crossover Participants (Nab-Paclitaxel+Carboplatin)		Arm B With Crossover Participants (Nab-Paclitaxel+Carboplatin, After Crossover Atezo Monotherapy)
	Affected / at Risk (%)		Affected / at Risk (%)		Affected / at Risk (%)
Total	338/473 (71.46%)		108/131 (82.44%)		70/101 (69.31%)
Serious Adverse Events
	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)		Arm B Without Crossover Participants (Nab-Paclitaxel+Carboplatin)		Arm B With Crossover Participants (Nab-Paclitaxel+Carboplatin, After Crossover Atezo Monotherapy)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	252/473 (53.28%)		63/131 (48.09%)		24/101 (23.76%)
Blood and lymphatic system disorders
AGRANULOCYTOSIS † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
ANAEMIA † 1	14/473 (2.96%)	16	4/131 (3.05%)	4	4/101 (3.96%)	4
FEBRILE NEUTROPENIA † 1	9/473 (1.90%)	10	3/131 (2.29%)	3	2/101 (1.98%)	2
HAEMOLYTIC URAEMIC SYNDROME † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
LEUKOPENIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
NEUTROPENIA † 1	14/473 (2.96%)	16	1/131 (0.76%)	1	1/101 (0.99%)	1
PANCYTOPENIA † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
THROMBOCYTOPENIA † 1	6/473 (1.27%)	6	0/131 (0.00%)	0	0/101 (0.00%)	0
Cardiac disorders
ACUTE CORONARY SYNDROME † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ACUTE MYOCARDIAL INFARCTION † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
ANGINA UNSTABLE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ATRIAL FIBRILLATION † 1	4/473 (0.85%)	4	1/131 (0.76%)	1	0/101 (0.00%)	0
ATRIAL FLUTTER † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
BRADYCARDIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CARDIAC ANEURYSM † 1	0/473 (0.00%)	0	0/131 (0.00%)	0	1/101 (0.99%)	1
CARDIAC ARREST † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
CARDIAC FAILURE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CARDIAC FAILURE CHRONIC † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
CARDIAC TAMPONADE † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
CARDIO-RESPIRATORY ARREST † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
MYOCARDIAL INFARCTION † 1	3/473 (0.63%)	3	1/131 (0.76%)	1	0/101 (0.00%)	0
PALPITATIONS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
PERICARDIAL EFFUSION † 1	6/473 (1.27%)	6	0/131 (0.00%)	0	0/101 (0.00%)	0
SUPRAVENTRICULAR TACHYCARDIA † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
VENTRICULAR TACHYCARDIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Ear and labyrinth disorders
VERTIGO † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Endocrine disorders
ADDISON'S DISEASE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
GLUCOCORTICOID DEFICIENCY † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HYPOTHYROIDISM † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
Gastrointestinal disorders
ABDOMINAL PAIN † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	0/101 (0.00%)	0
ABDOMINAL PAIN LOWER † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ABDOMINAL PAIN UPPER † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
COLITIS † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
CONSTIPATION † 1	3/473 (0.63%)	5	1/131 (0.76%)	1	0/101 (0.00%)	0
DIARRHOEA † 1	14/473 (2.96%)	14	1/131 (0.76%)	1	1/101 (0.99%)	1
DUODENAL ULCER † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
GASTRITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	1/101 (0.99%)	1
GASTROINTESTINAL HAEMORRHAGE † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
GASTROINTESTINAL VASCULAR MALFORMATION HAEMORRHAGIC † 1	0/473 (0.00%)	0	0/131 (0.00%)	0	1/101 (0.99%)	1
GASTROOESOPHAGEAL REFLUX DISEASE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ILEUS PARALYTIC † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
IMMUNE-MEDIATED ENTEROCOLITIS † 1	2/473 (0.42%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
LARGE INTESTINAL OBSTRUCTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
LARGE INTESTINAL STENOSIS † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
MELAENA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
NAUSEA † 1	5/473 (1.06%)	5	3/131 (2.29%)	4	1/101 (0.99%)	1
OESOPHAGEAL FOOD IMPACTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
SMALL INTESTINAL OBSTRUCTION † 1	0/473 (0.00%)	0	2/131 (1.53%)	2	0/101 (0.00%)	0
STOMATITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
UPPER GASTROINTESTINAL HAEMORRHAGE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
VOMITING † 1	6/473 (1.27%)	7	3/131 (2.29%)	4	1/101 (0.99%)	1
General disorders
ASTHENIA † 1	3/473 (0.63%)	5	0/131 (0.00%)	0	0/101 (0.00%)	0
CHEST PAIN † 1	5/473 (1.06%)	5	0/131 (0.00%)	0	0/101 (0.00%)	0
DEATH † 1	1/473 (0.21%)	1	3/131 (2.29%)	3	0/101 (0.00%)	0
DRUG INTERACTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
FATIGUE † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	1/101 (0.99%)	1
GENERAL PHYSICAL HEALTH DETERIORATION † 1	4/473 (0.85%)	4	1/131 (0.76%)	1	1/101 (0.99%)	1
GENERALISED OEDEMA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
INFLUENZA LIKE ILLNESS † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
MUCOSAL INFLAMMATION † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
NON-CARDIAC CHEST PAIN † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
OEDEMA PERIPHERAL † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
PAIN † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
PERFORMANCE STATUS DECREASED † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
PYREXIA † 1	8/473 (1.69%)	9	2/131 (1.53%)	2	0/101 (0.00%)	0
SUDDEN DEATH † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Hepatobiliary disorders
AUTOIMMUNE HEPATITIS † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
BILE DUCT STONE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CHOLECYSTITIS ACUTE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CHOLESTASIS † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	0/101 (0.00%)	0
HEPATIC CIRRHOSIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HEPATITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HEPATOCELLULAR INJURY † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
IMMUNE-MEDIATED HEPATITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Immune system disorders
ANAPHYLACTIC REACTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Infections and infestations
APPENDICITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
APPENDICITIS PERFORATED † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ATYPICAL PNEUMONIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
BACTERAEMIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
BACTERIAL COLITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
BACTERIAL SEPSIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
BRONCHITIS † 1	6/473 (1.27%)	6	0/131 (0.00%)	0	1/101 (0.99%)	1
CAMPYLOBACTER INFECTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CELLULITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CLOSTRIDIUM DIFFICILE COLITIS † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
CLOSTRIDIUM DIFFICILE INFECTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CONJUNCTIVITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CYSTITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CYTOMEGALOVIRUS COLITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
DEVICE RELATED INFECTION † 1	2/473 (0.42%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
DIVERTICULITIS † 1	0/473 (0.00%)	0	0/131 (0.00%)	0	1/101 (0.99%)	1
ENCEPHALITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ERYSIPELAS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
FEBRILE INFECTION † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
FURUNCLE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
GANGRENE † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
INFECTION † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	0/101 (0.00%)	0
INFECTIOUS PLEURAL EFFUSION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
INFLUENZA † 1	5/473 (1.06%)	5	1/131 (0.76%)	1	0/101 (0.00%)	0
NASOPHARYNGITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
NEUTROPENIC INFECTION † 1	0/473 (0.00%)	0	0/131 (0.00%)	0	1/101 (0.99%)	1
PARAPHARYNGEAL SPACE INFECTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
PNEUMONIA † 1	45/473 (9.51%)	55	13/131 (9.92%)	15	2/101 (1.98%)	2
PULMONARY SEPSIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
RESPIRATORY TRACT INFECTION † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	1/101 (0.99%)	1
SEPSIS † 1	7/473 (1.48%)	7	2/131 (1.53%)	2	0/101 (0.00%)	0
SEPTIC SHOCK † 1	5/473 (1.06%)	5	2/131 (1.53%)	2	0/101 (0.00%)	0
STAPHYLOCOCCAL SEPSIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
TOOTH INFECTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
TRACHEOBRONCHITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
UPPER RESPIRATORY TRACT INFECTION † 1	3/473 (0.63%)	4	0/131 (0.00%)	0	0/101 (0.00%)	0
URINARY TRACT INFECTION † 1	4/473 (0.85%)	4	1/131 (0.76%)	1	0/101 (0.00%)	0
UROSEPSIS † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
VASCULAR DEVICE INFECTION † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
Injury, poisoning and procedural complications
FALL † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
FEMORAL NECK FRACTURE † 1	0/473 (0.00%)	0	0/131 (0.00%)	0	1/101 (0.99%)	1
FEMUR FRACTURE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
INFUSION RELATED REACTION † 1	3/473 (0.63%)	4	0/131 (0.00%)	0	0/101 (0.00%)	0
LUMBAR VERTEBRAL FRACTURE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
PELVIC FRACTURE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
SPINAL COMPRESSION FRACTURE † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
SPINAL FRACTURE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
UPPER LIMB FRACTURE † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
Investigations
ALANINE AMINOTRANSFERASE INCREASED † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ASPARTATE AMINOTRANSFERASE INCREASED † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
BLOOD ALKALINE PHOSPHATASE INCREASED † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
BLOOD CREATININE INCREASED † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
BLOOD GLUCOSE INCREASED † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
LIPASE INCREASED † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
LYMPHOCYTE COUNT DECREASED † 1	1/473 (0.21%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
NEUTROPHIL COUNT DECREASED † 1	6/473 (1.27%)	6	0/131 (0.00%)	0	0/101 (0.00%)	0
PLATELET COUNT DECREASED † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	0/101 (0.00%)	0
WHITE BLOOD CELL COUNT DECREASED † 1	4/473 (0.85%)	4	0/131 (0.00%)	0	0/101 (0.00%)	0
Metabolism and nutrition disorders
DECREASED APPETITE † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	1/101 (0.99%)	1
DEHYDRATION † 1	3/473 (0.63%)	3	2/131 (1.53%)	2	0/101 (0.00%)	0
DIABETES MELLITUS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
DIABETIC KETOACIDOSIS † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
HYPERGLYCAEMIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HYPERKALAEMIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HYPOALBUMINAEMIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HYPOCALCAEMIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HYPOKALAEMIA † 1	3/473 (0.63%)	5	2/131 (1.53%)	2	0/101 (0.00%)	0
HYPOMAGNESAEMIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HYPONATRAEMIA † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
TYPE 2 DIABETES MELLITUS † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
Musculoskeletal and connective tissue disorders
ARTHRALGIA † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
BACK PAIN † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
BONE PAIN † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
LUMBAR SPINAL STENOSIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
MUSCULAR WEAKNESS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
MUSCULOSKELETAL CHEST PAIN † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
MYALGIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
SPINAL PAIN † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA OF COLON † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
NON-SMALL CELL LUNG CANCER † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
SARCOMA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
TUMOUR PAIN † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Nervous system disorders
ATAXIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CAROTID ARTERY STENOSIS † 1	1/473 (0.21%)	1	1/131 (0.76%)	1	0/101 (0.00%)	0
CEREBROVASCULAR ACCIDENT † 1	4/473 (0.85%)	4	2/131 (1.53%)	3	0/101 (0.00%)	0
DIZZINESS † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
EMBOLIC STROKE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
EPILEPSY † 1	2/473 (0.42%)	3	1/131 (0.76%)	1	0/101 (0.00%)	0
HEADACHE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HEMIPARESIS † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	0/101 (0.00%)	0
ISCHAEMIC STROKE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
LETHARGY † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
PARAESTHESIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
SEIZURE † 1	3/473 (0.63%)	3	0/131 (0.00%)	0	0/101 (0.00%)	0
SYNCOPE † 1	3/473 (0.63%)	3	1/131 (0.76%)	1	0/101 (0.00%)	0
TOXIC NEUROPATHY † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
TRANSIENT ISCHAEMIC ATTACK † 1	1/473 (0.21%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
VASOGENIC CEREBRAL OEDEMA † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
Psychiatric disorders
CONFUSIONAL STATE † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
DISORIENTATION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
MENTAL STATUS CHANGES † 1	4/473 (0.85%)	4	0/131 (0.00%)	0	0/101 (0.00%)	0
Renal and urinary disorders
ACUTE KIDNEY INJURY † 1	4/473 (0.85%)	4	0/131 (0.00%)	0	0/101 (0.00%)	0
AUTOIMMUNE NEPHRITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
NEPHRITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
NEPHROLITHIASIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
NEPHROPATHY TOXIC † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
POSTRENAL FAILURE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
RENAL FAILURE † 1	5/473 (1.06%)	5	1/131 (0.76%)	1	1/101 (0.99%)	1
TUBULOINTERSTITIAL NEPHRITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
URINARY RETENTION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Reproductive system and breast disorders
VAGINAL HAEMORRHAGE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY FAILURE † 1	3/473 (0.63%)	4	0/131 (0.00%)	0	0/101 (0.00%)	0
ASPIRATION † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ASTHMA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE † 1	13/473 (2.75%)	22	5/131 (3.82%)	8	0/101 (0.00%)	0
COUGH † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	1/101 (0.99%)	1
DYSPNOEA † 1	12/473 (2.54%)	12	1/131 (0.76%)	1	0/101 (0.00%)	0
EPISTAXIS † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
HAEMOPTYSIS † 1	6/473 (1.27%)	8	3/131 (2.29%)	4	0/101 (0.00%)	0
HYPOXIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
INTERSTITIAL LUNG DISEASE † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
LUNG DISORDER † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
ORGANISING PNEUMONIA † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
OROPHARYNGEAL DISCOMFORT † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
PLEURAL EFFUSION † 1	8/473 (1.69%)	8	0/131 (0.00%)	0	0/101 (0.00%)	0
PNEUMONITIS † 1	9/473 (1.90%)	9	2/131 (1.53%)	2	1/101 (0.99%)	1
PNEUMOTHORAX † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	2/101 (1.98%)	2
PNEUMOTHORAX SPONTANEOUS † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
PULMONARY EMBOLISM † 1	17/473 (3.59%)	18	3/131 (2.29%)	3	2/101 (1.98%)	2
PULMONARY HAEMORRHAGE † 1	2/473 (0.42%)	4	0/131 (0.00%)	0	0/101 (0.00%)	0
RESPIRATORY DISTRESS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
RESPIRATORY FAILURE † 1	3/473 (0.63%)	3	2/131 (1.53%)	2	0/101 (0.00%)	0
Skin and subcutaneous tissue disorders
DRUG ERUPTION † 1	0/473 (0.00%)	0	1/131 (0.76%)	1	0/101 (0.00%)	0
RASH † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
SKIN ULCER † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Surgical and medical procedures
ABORTION INDUCED † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
Vascular disorders
ARTERIAL OCCLUSIVE DISEASE † 1	1/473 (0.21%)	1	2/131 (1.53%)	2	0/101 (0.00%)	0
DEEP VEIN THROMBOSIS † 1	2/473 (0.42%)	2	0/131 (0.00%)	0	0/101 (0.00%)	0
EMBOLISM † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	0/101 (0.00%)	0
FEMORAL ARTERY ANEURYSM † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
HYPOTENSION † 1	2/473 (0.42%)	2	1/131 (0.76%)	1	0/101 (0.00%)	0
JUGULAR VEIN THROMBOSIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
PHLEBITIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
VASCULAR STENOSIS † 1	1/473 (0.21%)	1	0/131 (0.00%)	0	0/101 (0.00%)	0
1 Term from vocabulary, MedDRA version 23.1; † Indicates events were collected by systematic assessment
Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events	5%
	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)		Arm B Without Crossover Participants (Nab-Paclitaxel+Carboplatin)		Arm B With Crossover Participants (Nab-Paclitaxel+Carboplatin, After Crossover Atezo Monotherapy)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	467/473 (98.73%)		127/131 (96.95%)		100/101 (99.01%)
Blood and lymphatic system disorders
ANAEMIA † 1	259/473 (54.76%)	357	67/131 (51.15%)	79	50/101 (49.50%)	55
LEUKOPENIA † 1	51/473 (10.78%)	92	13/131 (9.92%)	22	6/101 (5.94%)	7
NEUTROPENIA † 1	213/473 (45.03%)	424	52/131 (39.69%)	95	53/101 (52.48%)	99
THROMBOCYTOPENIA † 1	132/473 (27.91%)	210	29/131 (22.14%)	49	31/101 (30.69%)	47
Ear and labyrinth disorders
VERTIGO † 1	17/473 (3.59%)	21	2/131 (1.53%)	2	7/101 (6.93%)	7
Endocrine disorders
HYPOTHYROIDISM † 1	51/473 (10.78%)	55	1/131 (0.76%)	1	0/101 (0.00%)	0
Eye disorders
VISION BLURRED † 1	25/473 (5.29%)	28	2/131 (1.53%)	2	4/101 (3.96%)	4
Gastrointestinal disorders
ABDOMINAL PAIN † 1	54/473 (11.42%)	67	9/131 (6.87%)	11	8/101 (7.92%)	9
ABDOMINAL PAIN UPPER † 1	25/473 (5.29%)	33	5/131 (3.82%)	7	6/101 (5.94%)	7
CONSTIPATION † 1	176/473 (37.21%)	224	38/131 (29.01%)	47	33/101 (32.67%)	42
DIARRHOEA † 1	196/473 (41.44%)	321	37/131 (28.24%)	61	35/101 (34.65%)	41
DRY MOUTH † 1	24/473 (5.07%)	24	3/131 (2.29%)	3	2/101 (1.98%)	2
DYSPEPSIA † 1	33/473 (6.98%)	34	2/131 (1.53%)	2	5/101 (4.95%)	6
GASTROOESOPHAGEAL REFLUX DISEASE † 1	24/473 (5.07%)	25	2/131 (1.53%)	3	4/101 (3.96%)	4
NAUSEA † 1	236/473 (49.89%)	354	61/131 (46.56%)	85	44/101 (43.56%)	65
STOMATITIS † 1	40/473 (8.46%)	45	8/131 (6.11%)	9	4/101 (3.96%)	5
VOMITING † 1	130/473 (27.48%)	228	25/131 (19.08%)	38	18/101 (17.82%)	30
General disorders
ASTHENIA † 1	89/473 (18.82%)	133	19/131 (14.50%)	26	21/101 (20.79%)	29
CHEST PAIN † 1	33/473 (6.98%)	43	10/131 (7.63%)	10	2/101 (1.98%)	2
CHILLS † 1	25/473 (5.29%)	32	4/131 (3.05%)	4	3/101 (2.97%)	4
FATIGUE † 1	228/473 (48.20%)	297	57/131 (43.51%)	73	52/101 (51.49%)	61
MUCOSAL INFLAMMATION † 1	24/473 (5.07%)	26	4/131 (3.05%)	5	4/101 (3.96%)	4
OEDEMA PERIPHERAL † 1	71/473 (15.01%)	81	14/131 (10.69%)	17	11/101 (10.89%)	13
PAIN † 1	30/473 (6.34%)	33	6/131 (4.58%)	7	2/101 (1.98%)	3
PYREXIA † 1	80/473 (16.91%)	104	12/131 (9.16%)	16	10/101 (9.90%)	15
Infections and infestations
BRONCHITIS † 1	29/473 (6.13%)	30	2/131 (1.53%)	2	4/101 (3.96%)	5
NASOPHARYNGITIS † 1	38/473 (8.03%)	61	4/131 (3.05%)	4	6/101 (5.94%)	7
PNEUMONIA † 1	37/473 (7.82%)	41	6/131 (4.58%)	6	2/101 (1.98%)	2
UPPER RESPIRATORY TRACT INFECTION † 1	35/473 (7.40%)	55	8/131 (6.11%)	9	4/101 (3.96%)	6
URINARY TRACT INFECTION † 1	63/473 (13.32%)	91	9/131 (6.87%)	9	10/101 (9.90%)	11
Injury, poisoning and procedural complications
FALL † 1	24/473 (5.07%)	33	4/131 (3.05%)	4	0/101 (0.00%)	0
Investigations
ALANINE AMINOTRANSFERASE INCREASED † 1	26/473 (5.50%)	42	9/131 (6.87%)	13	5/101 (4.95%)	5
BLOOD CREATININE INCREASED † 1	27/473 (5.71%)	32	7/131 (5.34%)	11	1/101 (0.99%)	2
NEUTROPHIL COUNT DECREASED † 1	93/473 (19.66%)	188	18/131 (13.74%)	33	17/101 (16.83%)	29
PLATELET COUNT DECREASED † 1	108/473 (22.83%)	179	22/131 (16.79%)	29	16/101 (15.84%)	32
WEIGHT DECREASED † 1	63/473 (13.32%)	71	15/131 (11.45%)	16	13/101 (12.87%)	13
WHITE BLOOD CELL COUNT DECREASED † 1	49/473 (10.36%)	80	9/131 (6.87%)	16	9/101 (8.91%)	12
ASPARTATE AMINOTRANSFERASE INCREASED † 1	20/473 (4.23%)	30	8/131 (6.11%)	10	1/101 (0.99%)	1
Metabolism and nutrition disorders
DECREASED APPETITE † 1	144/473 (30.44%)	169	34/131 (25.95%)	36	30/101 (29.70%)	34
DEHYDRATION † 1	52/473 (10.99%)	73	17/131 (12.98%)	27	8/101 (7.92%)	8
HYPOKALAEMIA † 1	77/473 (16.28%)	98	12/131 (9.16%)	13	12/101 (11.88%)	16
HYPOMAGNESAEMIA † 1	94/473 (19.87%)	130	23/131 (17.56%)	27	17/101 (16.83%)	23
HYPONATRAEMIA † 1	31/473 (6.55%)	54	8/131 (6.11%)	10	0/101 (0.00%)	0
HYPOPHOSPHATAEMIA † 1	20/473 (4.23%)	32	7/131 (5.34%)	8	1/101 (0.99%)	1
Musculoskeletal and connective tissue disorders
ARTHRALGIA † 1	113/473 (23.89%)	161	19/131 (14.50%)	20	17/101 (16.83%)	20
BACK PAIN † 1	89/473 (18.82%)	105	9/131 (6.87%)	9	7/101 (6.93%)	7
MUSCULAR WEAKNESS † 1	25/473 (5.29%)	27	8/131 (6.11%)	10	6/101 (5.94%)	6
MYALGIA † 1	50/473 (10.57%)	60	5/131 (3.82%)	5	5/101 (4.95%)	7
PAIN IN EXTREMITY † 1	61/473 (12.90%)	72	7/131 (5.34%)	7	8/101 (7.92%)	8
Nervous system disorders
DIZZINESS † 1	78/473 (16.49%)	90	14/131 (10.69%)	21	11/101 (10.89%)	15
DYSGEUSIA † 1	43/473 (9.09%)	46	5/131 (3.82%)	5	7/101 (6.93%)	7
HEADACHE † 1	85/473 (17.97%)	106	12/131 (9.16%)	13	11/101 (10.89%)	13
NEUROPATHY PERIPHERAL † 1	56/473 (11.84%)	58	13/131 (9.92%)	16	9/101 (8.91%)	10
PARAESTHESIA † 1	43/473 (9.09%)	51	7/131 (5.34%)	7	5/101 (4.95%)	6
PERIPHERAL SENSORY NEUROPATHY † 1	60/473 (12.68%)	71	10/131 (7.63%)	14	13/101 (12.87%)	15
Psychiatric disorders
ANXIETY † 1	32/473 (6.77%)	32	4/131 (3.05%)	4	3/101 (2.97%)	3
DEPRESSION † 1	29/473 (6.13%)	29	5/131 (3.82%)	5	0/101 (0.00%)	0
INSOMNIA † 1	70/473 (14.80%)	76	15/131 (11.45%)	17	16/101 (15.84%)	16
Respiratory, thoracic and mediastinal disorders
COUGH † 1	135/473 (28.54%)	162	21/131 (16.03%)	21	18/101 (17.82%)	21
DYSPNOEA † 1	134/473 (28.33%)	181	28/131 (21.37%)	30	23/101 (22.77%)	29
EPISTAXIS † 1	69/473 (14.59%)	84	17/131 (12.98%)	18	10/101 (9.90%)	12
HAEMOPTYSIS † 1	30/473 (6.34%)	42	6/131 (4.58%)	6	2/101 (1.98%)	2
PNEUMONITIS † 1	24/473 (5.07%)	26	0/131 (0.00%)	0	0/101 (0.00%)	0
PRODUCTIVE COUGH † 1	35/473 (7.40%)	44	4/131 (3.05%)	4	4/101 (3.96%)	4
Skin and subcutaneous tissue disorders
ALOPECIA † 1	152/473 (32.14%)	155	33/131 (25.19%)	33	30/101 (29.70%)	30
DRY SKIN † 1	28/473 (5.92%)	31	6/131 (4.58%)	6	6/101 (5.94%)	6
PRURITUS † 1	61/473 (12.90%)	81	7/131 (5.34%)	7	5/101 (4.95%)	5
RASH † 1	73/473 (15.43%)	86	6/131 (4.58%)	7	11/101 (10.89%)	12
RASH MACULO-PAPULAR † 1	20/473 (4.23%)	21	7/131 (5.34%)	8	1/101 (0.99%)	2
Vascular disorders
HYPERTENSION † 1	26/473 (5.50%)	33	3/131 (2.29%)	4	5/101 (4.95%)	6
HYPOTENSION † 1	34/473 (7.19%)	43	6/131 (4.58%)	8	7/101 (6.93%)	7
1 Term from vocabulary, MedDRA version 23.1; † Indicates events were collected by systematic assessment

Limitations and Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Results Point of Contact

• Name/Title: Medical Communications
• Organization: Hoffmann-La Roche
• Phone: 800-821-8590
• EMail: genentech@druginfo.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ton TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, Sadetsky N, Chaudhary N, Lu MW, Riely GJ. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res. 2022 Jul 1;28(13):2844-2853. doi: 10.1158/1078-0432.CCR-22-0471.

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.

• Responsible Party: Hoffmann-La Roche
• ClinicalTrials.gov Identifier: NCT02367781
• Other Study ID Numbers: GO29537; 2014-003206-32 ( EudraCT Number )
• First Submitted: February 13, 2015
• First Posted: February 20, 2015
• Results First Submitted: March 13, 2019
• Results First Posted: April 3, 2019
• Last Update Posted: August 9, 2021